Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Onvansertib (Primary) ; Abiraterone acetate; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms UNITE
  • Sponsors TrovaGene
  • Most Recent Events

    • 18 Oct 2018 According to a TrovaGene media release, the company will present an updated data from this study at a a live conference call and webcast.
    • 31 Aug 2018 Biomarkers information updated
    • 01 Aug 2018 According to a Trovagene media release, the trial was accepted by the National Library of Medicine (NLM).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top